Form 4: CERo Therapeutics CEO Granted Stock Options; Power of Attorney Filed for SEC Compliance

Christopher B. Ehlich, Chairman and CEO of CERo Therapeutics Holdings, Inc., was granted 61,843 stock options at an exercise price of $0.4454, with a portion vesting monthly and the remainder subject to performance conditions, as detailed in a recent Form 4 filing.

Summary

• Christopher B. Ehlich, Chairman and CEO of CERo Therapeutics Holdings, Inc. (CERO), is the reporting person for the Form 4 filing.
• He was granted 61,843 stock options (Right to Buy) on May 30, 2025, with an exercise price of $0.4454.
• These options have an expiration date of May 29, 2035.
• The 61,843 options represent the 1/3 time-based portion of a larger award totaling 185,529 shares.
• The time-based portion of the options will vest in equal monthly installments on the 4th of each month, starting from July 4, 2025, through December 4, 2025.
• The remaining portion of the 185,529 shares is subject to specific performance conditions.
• A Limited Power of Attorney was filed, appointing Andrew Albert Kucharchuk as the attorney-in-fact for Christopher B. Ehlich to execute and file various U.S. Securities and Exchange Commission (SEC) forms, including Form ID, Form 3, Form 4, Form 5, and Schedules 13D and 13G.

Sentiment

Score: 6

Explanation: The filing is largely administrative (Power of Attorney) and a routine disclosure of executive compensation (stock option grant). The option grant itself is a positive for aligning management incentives with shareholder value, but it doesn't contain new operational or financial performance data that would significantly alter the company's outlook.

Positives

• The grant of stock options to the Chairman and CEO aligns his financial interests with those of the shareholders, incentivizing long-term company performance.
• The combination of time-based and performance-based vesting conditions for the option award encourages both sustained commitment and the achievement of strategic company goals.

Risks

• The reporting person (Christopher B. Ehlich) retains full responsibility for complying with Section 16 and Regulation 13D-G of the Securities Exchange Act of 1934, as the attorneys-in-fact and the Company are not assuming these responsibilities.
• The undersigned agrees to indemnify the attorneys-in-fact and the Company against any demand, damage, loss, cost, or expense arising from any false or misleading information provided by the undersigned to the attorneys-in-fact for SEC filings.

Future Outlook

The vesting schedule for the stock options, extending from July 2025 to December 2025 for the time-based portion and with performance conditions for the remainder, indicates an expectation of continued employment and performance from the CEO.

Management Comments

• "The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigneds responsibilities to comply with Section 16 or Regulation 13D-G of the Securities Exchange Act of 1934, as amended."
• "The undersigned hereby agrees to indemnify the attorneys-in-fact and the Company from and against any demand, damage, loss, cost or expense arising from any false or misleading information provided by the undersigned to the attorneys-in-fact."

Industry Context

This filing represents a routine disclosure of executive equity compensation and a standard corporate governance action (Power of Attorney) within the public company landscape. It reflects common practices for aligning executive incentives with shareholder interests through stock option grants, typical across various industries, including biotechnology or pharmaceuticals, where such compensation structures are prevalent.

Corporate Governance

Related Party Transactions

• Grant of 61,843 stock options to Christopher B. Ehlich, Chairman and CEO, at an exercise price of $0.4454, as part of a larger award of 185,529 shares, with vesting conditions.

Stakeholder Impact

• Shareholders: The grant of stock options to the Chairman and CEO aligns management's long-term incentives with shareholder value, potentially fostering improved company performance and encouraging retention of key leadership.

Next Steps

• Monthly vesting of the time-based portion of the stock options will occur from July 4, 2025, through December 4, 2025.
• The performance conditions for the remaining portion of the option award will need to be met for those shares to vest.
• The appointed attorney-in-fact will continue to file required SEC forms (Form 3, 4, 5, 13D/G) on behalf of Christopher B. Ehlich as necessary.

Key Dates

Keywords

CERo Therapeutics, CERO, Stock Option, Form 4, SEC Filing, Beneficial Ownership, Executive Compensation, Corporate Governance, Power of Attorney, Insider Transaction, Section 16